Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases

The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology Vol. 71; no. 5; p. 564
Main Authors: Kishore, Sandeep P, Blank, Evan, Heller, David J, Patel, Amisha, Peters, Alexander, Price, Matthew, Vidula, Mahesh, Fuster, Valentin, Onuma, Oyere, Huffman, Mark D, Vedanthan, Rajesh
Format: Journal Article
Language:English
Published: United States 06.02.2018
Subjects:
Cardiovascular Diseases - prevention & control
Drugs, Essential - therapeutic use
Formularies as Topic
Humans
World Health Organization
NCDs
cardiovascular disease
essential medicines
WHO Essential Medicines List
ISSN:1558-3597, 1558-3597
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The World Health Organization (WHO) Model List of Essential Medicines (EML) is a key tool for improving global access to medicines for all conditions, including cardiovascular diseases (CVDs). The WHO EML is used by member states to determine their national essential medicine lists and policies and to guide procurement of medicines in the public sector. Here, we describe our efforts to modernize the EML for global CVD prevention and control. We review the recent history of applications to add, delete, and change indications for CVD medicines, with the aim of aligning the list with contemporary clinical practice guidelines. We have identified 4 issues that affect decisions for the EML and may strengthen future applications: 1) cost and cost-effectiveness; 2) presence in clinical practice guidelines; 3) feedback loops; and 4) community engagement. We share our lessons to stimulate others in the global CVD community to embark on similar efforts.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1558-3597
1558-3597
DOI:10.1016/j.jacc.2017.11.056